Key Update
The MHRA has issued updated guidance on systemic fluoroquinolone antibiotics, effective immediately. These agents must now be prescribed only when other commonly recommended antibiotics are inappropriate.
What Has Changed?
Following a comprehensive safety review, fluoroquinolones are no longer considered first-line or routine options for bacterial infections. This restriction reflects the balance between their benefits and known risks, particularly in relation to serious adverse effects that can affect multiple body systems.
Affected Medications
This guidance applies to systemic fluoroquinolones, including:
- Ciprofloxacin
- Levofloxacin
- Moxifloxacin
- Ofloxacin
- Other fluoroquinolone agents for systemic use
What You Need to Do
- Review current prescribing practice: Audit any ongoing fluoroquinolone courses and consider whether alternatives are now more appropriate.
- Communicate with patients: If patients are currently taking fluoroquinolones, discuss whether continuation is necessary or if switching is advisable.
- Update protocols: Ensure local antibiotic stewardship guidelines reflect this change in status.
- Stay informed: Share this update with your team and ensure all prescribers are aware of the new restrictions.
Further Information
For the full MHRA alert and detailed safety information, visit the MHRA Drug Safety Update.